Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact

Por de Vrueh, Remco L. A., Crommelin, Daan J. A.
Publicado no Pharm Res (2017)

Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

Por Brabers, Anne EM, Moors, Ellen HM, van Weely, Sonja, de Vrueh, Remco LA
Publicado em 2011

Predictors of orphan drug approval in the European Union

Por Heemstra, Harald E., de Vrueh, Remco L., van Weely, Sonja, Büller, Hans A., Leufkens, Hubert G. M.
Publicado em 2008

Product development programs for neglected tropical diseases: A crucial role for expert meetings

Por Hussaarts, Leonie, van der Weijde, Kim, Dome, Pierre, Kourany-Lefoll, Elly, Reinhard-Rupp, Jutta, de Vrueh, Remco
Publicado no PLoS Negl Trop Dis (2017)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible

Por Putzeist, Michelle, Mantel-Teeuwisse, Aukje K, Wied, Christine C Gispen-de, Hoes, Arno W, Leufkens, Hubert GM, de Vrueh, Remco LA
Publicado em 2013

Carrier-Mediated Delivery of 9-(2-Phosphonylmethoxyethyl)Adenine to Parenchymal Liver Cells: a Novel Therapeutic Approach for Hepatitis B

Por de Vrueh, Remco L. A., Rump, Erik T., van de Bilt, Erika, van Veghel, Richard, Balzarini, Jan, Biessen, Erik A. L., van Berkel, Theo J. C., Bijsterbosch, Martin K.
Publicado em 2000